Ponesimod for moderate to severe plaque psoriasis
Part of Skin clinical trials.
This trial tests an investigational drug called ponesimod for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at improving skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your body mass index (BMI) is between 18 and 40.
- Your psoriasis covers at least 10% of your body.
- Your psoriasis severity scores are at certain levels (PASI 12+ or PGA 3+).
- You have been diagnosed with moderate-to-severe plaque psoriasis (not other types like pustular or guttate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests a new medicine (HS-20137) for moderate-to-severe plaque psoriasis, a condition causing thick, scaly patches on the skin. It aims to see if this medicine can safely reduce the severity of psoriasis and improve quality of life.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
Hear when a new Moderate-to-severe Chronic Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.